phytogenic antineoplastic agents

Summary

Summary: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Top Publications

  1. ncbi Paclitaxel and docetaxel in prostate cancer
    C Obasaju
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Hematol Oncol Clin North Am 15:525-45. 2001
  2. ncbi Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer
    K J Pienta
    Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-0946, USA
    Semin Oncol 28:3-7. 2001
  3. ncbi Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test
    Takeshi Mori
    Department of Hospital Pharmacy, Aichi Medical University, School of Medicine, Nagakute cho, Aichi Gun, Aichi 480 1195, Japan
    Oncol Rep 9:301-5. 2002
  4. ncbi Three new C-14 oxygenated taxanes from the wood of Taxus yunnanensis
    Arjun H Banskota
    Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630-Sugitani, Toyama 930-0194, Japan
    J Nat Prod 65:1700-2. 2002
  5. ncbi Inhibition of cancer growth by resveratrol is related to its low bioavailability
    Miguel Asensi
    , Universidad de Valencia, Valencia, Spain
    Free Radic Biol Med 33:387-98. 2002
  6. ncbi Resveratrol-induced autophagocytosis in ovarian cancer cells
    Anthony W Opipari
    Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 64:696-703. 2004
  7. ncbi Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation
    Syed M Meeran
    Department of Dermatology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA
    Toxicol Appl Pharmacol 229:33-43. 2008
  8. ncbi Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
    David W Nyman
    Department of Pharmacology Toxicology, Division of Hematology Oncology, Arizona Cancer Center University of Arizona Health Sciences Center, Tucson, USA
    J Clin Oncol 23:7785-93. 2005
  9. ncbi A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS
    L Mu
    Division of Bioengineering, The National University of Singapore, 9 Engineering Drive 1, 117576, Singapore, Singapore
    J Control Release 86:33-48. 2003
  10. ncbi Cytotoxicity of plants from Malaysia and Thailand used traditionally to treat cancer
    C C Lee
    Department of Pharmacy, King's College London, London SE1 9NN, UK
    J Ethnopharmacol 100:237-43. 2005

Research Grants

  1. Molecular Target Focused Discovery of Anticancer Drugs
    George R Pettit; Fiscal Year: 2010
  2. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2007
  3. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2005
  4. Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
    Lars Wagner; Fiscal Year: 2007
  5. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
  6. Design of Gene Delivery System to Target Hepatocytes
    Mark Davis; Fiscal Year: 2007
  7. NATIONAL WILMS TUMOR STUDY -5
    Daniel Green; Fiscal Year: 2003
  8. Phase I Clinical Trials of Anti-Cancer Agents
    Mark Ratain; Fiscal Year: 2007
  9. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2007
  10. Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal Carcinoma
    Bach Ardalan; Fiscal Year: 2007

Detail Information

Publications245 found, 100 shown here

  1. ncbi Paclitaxel and docetaxel in prostate cancer
    C Obasaju
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Hematol Oncol Clin North Am 15:525-45. 2001
    ..Pharmacokinetic and pharmacodynamic studies will play a key role in the development of future taxane-based therapies for prostate cancer...
  2. ncbi Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer
    K J Pienta
    Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-0946, USA
    Semin Oncol 28:3-7. 2001
    ..Further elucidation of these differences will be instrumental in designing targeted regimens for the treatment of localized and advanced prostate cancer...
  3. ncbi Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test
    Takeshi Mori
    Department of Hospital Pharmacy, Aichi Medical University, School of Medicine, Nagakute cho, Aichi Gun, Aichi 480 1195, Japan
    Oncol Rep 9:301-5. 2002
    ..Results of this study suggest that the test method established by us can predict drug sensitivity and cell kill kinetics of the agents, and can be a useful tool in deciding appropriate treatment regimen for individual patients...
  4. ncbi Three new C-14 oxygenated taxanes from the wood of Taxus yunnanensis
    Arjun H Banskota
    Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630-Sugitani, Toyama 930-0194, Japan
    J Nat Prod 65:1700-2. 2002
    ..The isolates obtained were evaluated for their antiproliferative activity toward murine colon 26-L5 carcinoma and human HT-1080 fibrosarcoma cell lines...
  5. ncbi Inhibition of cancer growth by resveratrol is related to its low bioavailability
    Miguel Asensi
    , Universidad de Valencia, Valencia, Spain
    Free Radic Biol Med 33:387-98. 2002
    ....
  6. ncbi Resveratrol-induced autophagocytosis in ovarian cancer cells
    Anthony W Opipari
    Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 64:696-703. 2004
    ....
  7. ncbi Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation
    Syed M Meeran
    Department of Dermatology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA
    Toxicol Appl Pharmacol 229:33-43. 2008
    ....
  8. ncbi Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
    David W Nyman
    Department of Pharmacology Toxicology, Division of Hematology Oncology, Arizona Cancer Center University of Arizona Health Sciences Center, Tucson, USA
    J Clin Oncol 23:7785-93. 2005
    ..This study determined the maximum-tolerated dose (MTD) of ABI-007 monotherapy administered weekly (three weekly doses, repeated every 4 weeks) and assessed the pharmacokinetics of paclitaxel administered as ABI-007...
  9. ncbi A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS
    L Mu
    Division of Bioengineering, The National University of Singapore, 9 Engineering Drive 1, 117576, Singapore, Singapore
    J Control Release 86:33-48. 2003
    ..Nanoparticles of nanometer size with narrow distribution can be obtained. A drug encapsulation efficiency as high as 100% can be achieved and the release kinetics can be controlled...
  10. ncbi Cytotoxicity of plants from Malaysia and Thailand used traditionally to treat cancer
    C C Lee
    Department of Pharmacy, King's College London, London SE1 9NN, UK
    J Ethnopharmacol 100:237-43. 2005
    ..59 microM). The Malaysian Alpinia galanga showed weak activity compared with the Thai sample and this was shown to be due to the relatively high amounts of 1'-acetoxychavicol acetate present in the Thai sample...
  11. ncbi Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis
    X H Yang
    Lurie Cancer Center, Northwestern University Medical School, Evanston Northwestern Healthcare, Illinois 60201, USA
    Cancer Res 61:348-54. 2001
    ..Our results also suggest that caspase 3 deficiency may contribute to chemotherapeutic resistance in breast cancer...
  12. ncbi The biology of the combretastatins as tumour vascular targeting agents
    Gillian M Tozer
    Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
    Int J Exp Pathol 83:21-38. 2002
    ..This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential...
  13. ncbi Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles
    Lei Yang
    School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang City, Liaoning, China
    Int J Pharm 340:163-72. 2007
    ..These results suggest that the HCPT-BSA nanoparticles seem to be a stable delivery system for poorly soluble HCPT or its derivatives...
  14. ncbi Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage
    Noritaka Adachi
    Kihara Institute for Biological Research, Graduate School of Integrated Science, Yokohama City University, Totsuka ku, Yokohama 244 0813, Japan
    J Biol Chem 278:35897-902. 2003
    ..The outstandingly increased cytotoxicity of topo II inhibitors in the absence of NHEJ suggests that simultaneous inhibition of topo II and NHEJ would provide a powerful protocol in cancer chemotherapy involving topo II inhibitors...
  15. ncbi Mechanisms of antiprostate cancer by gum mastic: NF-kappaB signal as target
    Mei Lan He
    Institute of Cancer Research, Life Science and Technology School, Tongji University, Shanghai 200092, China
    Acta Pharmacol Sin 28:446-52. 2007
    ....
  16. ncbi Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion
    Zih Rou Huang
    Pharmaceutics Laboratory, Chang Gung University, Taoyuan, Taiwan, China
    Acta Pharmacol Sin 29:1094-102. 2008
    ..The aim of this study was to develop and characterize lipid nanoparticles with different lipid cores which can circumvent these problems...
  17. ncbi Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types
    Jan H Kessler
    Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Cancer Lett 251:132-45. 2007
    ..Our results substantiate the possible application of BA as a chemotherapeutic agent for the most prevalent human cancer types...
  18. ncbi Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells
    Wanzhou Zhao
    Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No1 Xiannong Tan Street, Beijing 100050, China
    Cancer Detect Prev 27:67-75. 2003
    ....
  19. ncbi Protein nanoparticles as drug carriers in clinical medicine
    Michael J Hawkins
    Abraxis Bioscience, Inc, Los Angeles, CA 90025, USA
    Adv Drug Deliv Rev 60:876-85. 2008
    ..The nab technology promises to have broad utility in cancer therapy, and clinical trials are underway using nab formulations of other water-insoluble anticancer agents such as docetaxel and rapamycin...
  20. ncbi Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
    S S Bacus
    Quantitative Diagnostic Laboratories, Inc, Elmhurst, Illinois 60126, USA
    Oncogene 20:147-55. 2001
    ..However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle...
  21. ncbi Effects of cryotherapy or chemotherapy on apoptosis in a non-small-cell lung cancer xenografted into SCID mice
    Valérie Forest
    UPRES EA3063, Faculte de Medecine Jacques Lisfranc, 15 rue Ambroise Paré, 42023 Saint Etienne cedex 2, France
    Cryobiology 50:29-37. 2005
    ..Taken together, these results demonstrate the differential effects of cryotherapy and chemotherapy in vivo, suggesting different modes of action and the potential benefit to combine them...
  22. ncbi Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia
    K V Balan
    Department of Biology, University of Miami, Coral Gables, Miami, FL, USA
    Phytomedicine 14:263-72. 2007
    ....
  23. ncbi Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents
    Yingming Li
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9110, USA
    J Urol 167:339-46. 2002
    ..CONCLUSIONS: The potential synergy of gene therapy with docetaxel and paclitaxel may be an important direction for future therapy for metastatic androgen independent prostate cancer...
  24. ncbi p53 expression and resistance against paclitaxel in patients with metastatic breast cancer
    M Schmidt
    Department of Obstetrics and Gynaecology, University Hospital Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany
    J Cancer Res Clin Oncol 129:295-302. 2003
    ..Identifying these patients could spare them an ineffective treatment and could in turn characterize a subgroup of patients with a higher response rate...
  25. ncbi Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
    ..Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life...
  26. ncbi AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol
    Shubha Anand
    CR UK Department of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison MRC Research Centre, University of Cambridge, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Cancer Cell 3:51-62. 2003
    ..Consistent with this conclusion, elevated Aurora-A expression causes resistance to apoptosis induced by Taxol in a human cancer cell line...
  27. ncbi Production of paclitaxel and the related taxanes by cell suspension cultures of Taxus species
    Homare Tabata
    Functional and Chemicals Laboratory, Mitsui Chemicals, Inc, 1144, Togo, Mobara shi, Japan
    Curr Drug Targets 7:453-61. 2006
    ..By applying the data from the two-stage culture and the high-density culture, a large-scale culture process was developed with a stable paclitaxel production in the range of 140-295 mg L(-1), reaching 295 mg L(-1) at maximum...
  28. ncbi Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells
    Hiroaki Kajiyama
    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
    Int J Oncol 31:277-83. 2007
    ..It is possible that therapeutic benefits such as the restoration of chemosensitivity or suppression of metastasis will be enabled by gaining further insight into the mechanisms underlying chemoresistance and EMT...
  29. ncbi Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    L Paz-Ares
    Hospital Universitario 12 de Octubre, Servicio de Oncologia Medica, Madrid 28041, Spain
    Br J Cancer 98:1608-13. 2008
    ..Paclitaxel poliglumex at a dose of 210 mg m(-2) resulted in increased neurotoxicity compared with docetaxel...
  30. ncbi Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines
    Kohji Takara
    Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmacutical University, Misasagi, Japan
    Biol Pharm Bull 25:771-8. 2002
    ..The 27 anticancer drugs analyzed here could be classified into substrates and nonsubstrates for MDR1. This will be useful for designing effective regimens for chemotherapy...
  31. ncbi "Will weekly work"? Seems to be so
    Andrew D Seidman
    J Clin Oncol 23:5873-4. 2005
  32. ncbi Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
    Heidi LeBlanc
    Department of Molecular Oncology, Genentech, South San Francisco, California, USA
    Nat Med 8:274-81. 2002
    ..Thus, Bax mutation in mismatch repair--deficient tumors can cause resistance to death receptor--targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity...
  33. ncbi The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells
    Roxane Engel
    Experimental Therapeutics Program, Departments of Interdisciplinary Oncology and Biochemistry and Molecular Biology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Exp Cell Res 295:421-31. 2004
    ..It appears that the nuclear-cytoplasmic shuttling of topo IIalpha, which decreases the amount of nuclear target enzyme, is a major mechanism of drug resistance to topo II inhibitors in plateau-phase myeloma cells...
  34. ncbi Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Nasser Hanna
    Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 22:1589-97. 2004
    ..To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy...
  35. ncbi Dietary polyphenolic phytochemicals--promising cancer chemopreventive agents in humans? A review of their clinical properties
    Sarah C Thomasset
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Leicester, UK
    Int J Cancer 120:451-8. 2007
    ....
  36. ncbi Antioxidant, antimicrobial and cytotoxic activities of selected medicinal plants from Yemen
    Mohamed Al Fatimi
    Faculty of Medicine and Health Sciences, Pharmacy Section, Department of Pharmacognosy, Aden University, Aden, Yemen
    J Ethnopharmacol 111:657-66. 2007
    ..Remarkable cytotoxic activity against FL-cells was shown only for five plants, among them Plicosepalus curviflorus (stems)...
  37. ncbi Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Jenny C Chang
    Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA
    Lancet 362:362-9. 2003
    ..Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel...
  38. ncbi Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest
    Lingling Duan
    Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Mail Slot 516, 4301 W Markham Street, Little Rock, AR 72205, United States
    Biochem Pharmacol 73:481-90. 2007
    ..These results indicate that c-Jun expression plays a protective role in the cellular response to vinblastine and operates post-mitotic block to inhibit drug-induced apoptosis and senescence...
  39. ncbi Treatment with 2-AAF blocks the small hepatocyte-like progenitor cell response in retrorsine-exposed rats
    D Hunter Best
    Department of Pathology and Laboratory Medicine, Curriculum in Toxicology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    J Hepatol 46:1055-63. 2007
    ....
  40. ncbi beta-Sitosterol activates Fas signaling in human breast cancer cells
    A B Awad
    Department of Exercise and Nutrition Sciences, State University of New York at Buffalo, Buffalo, NY 14214, USA
    Phytomedicine 14:747-54. 2007
    ..These findings support the hypothesis that beta-sitosterol is an effective apoptosis-promoting agent and that incorporation of more phytosterols in the diet may serve a preventive measure for breast cancer...
  41. ncbi In vitro cytotoxic activity of Brazilian plant extracts against human lung, colon and CNS solid cancers and leukemia
    Ivana B Suffredini
    Laboratório de Extração da Universidade Paulista UNIP, Sao Paulo, SP, Brazil
    Fitoterapia 78:223-6. 2007
    ..Expressive activity was observed in the extracts of Toulicia cf. pulvinata, Ampirrhox sp., Macoubea sprucei, Calophyllum brasiliense, Vismia guianensis, Caryocar microcarpum, Xylopia aromatica and Distictella magnoliifolia...
  42. ncbi Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin
    Jonathan P Carson
    Department of Genetics and Genomics, Boston University School of Medicine, Boston, Massachusetts, USA
    Cancer Res 64:2096-104. 2004
    ....
  43. ncbi In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel
    F Lacoeuille
    Inserm U646, 10 rue A Boquel, F 49100 Angers, France
    Int J Pharm 344:143-9. 2007
    ..These results demonstrate the great interest to use LNC as drug delivery system for paclitaxel, permitting with an equivalent therapeutic efficiency to avoid the use of excipients such as polyoxyethylated castor oil for its formulation...
  44. ncbi Are isothiocyanates potential anti-cancer drugs?
    Xiang Wu
    Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China
    Acta Pharmacol Sin 30:501-12. 2009
    ..This review summarizes the current knowledge on isothiocyanates and focuses on their role as potential anti-cancer agents...
  45. ncbi The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme
    Kyungsu Kang
    Natural Products Research Center, Korea Institute of Science and Technology, Gangneung 210 340, Korea
    Biol Pharm Bull 30:2352-9. 2007
    ..These data suggest that the extract as well as the lignan compounds (especially arctigenin) originated from Saussurea salicifolia may be served as potential cancer chemopreventive agents for prevention or treatment of human cancers...
  46. ncbi Back to basics: how natural products can provide the basis for new therapeutics
    Amit Deorukhkar
    The University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Expert Opin Investig Drugs 16:1753-73. 2007
    ..This review focuses on the mechanism of action of key natural products and promising preclinical data on their efficacy as anticancer agents, as single agents and in combination with standard therapies...
  47. ncbi Diallyl sulfide induces apoptosis in Colo 320 DM human colon cancer cells: involvement of caspase-3, NF-kappaB, and ERK-2
    Narayanan Sriram
    Department of Biochemistry, University of Madras, Guindy Campus, Chennai, Tamil Nadu 600 025, India
    Mol Cell Biochem 311:157-65. 2008
    ..In conclusion, DAS increased the production of ROS, caused cell cycle arrest, decreased cell proliferation and induced apoptosis in Colo 320 DM cells. Thus, this study put forward DAS as a drug that can possibly be used to treat cancers...
  48. ncbi Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases
    Y Tang
    Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom
    J Control Release 116:e55-6. 2006
  49. ncbi Purine-containing cucurbitane triterpenoids from Cucurbita pepo cv dayangua
    Da Cheng Wang
    School of Veterinary Science, Jilin University, Jilin 130062, China
    Phytochemistry 69:1434-8. 2008
    ..Cucurbitaglycosides A and B showed cytotoxic activity against the human epithelial carcinoma cell line HeLa with IC50 of 17.2 and 28.4 microg/mL, respectively...
  50. ncbi Synthesis and cytotoxicity of bidesmosidic betulin and betulinic acid saponins
    Charles Gauthier
    Laboratoire d Analyse et de Separation des Essences Vegetales LASEVE, Departement des Sciences Fondamentales, Universite du Quebec a Chicoutimi, Chicoutimi, Quebec, Canada, G7H 2B1
    J Nat Prod 72:72-81. 2009
    ..8-1.9 microM)...
  51. ncbi VP-16 resistance in the NCI-H460 human lung cancer cell line is significantly associated with glucose-regulated protein78 (GRP78) induction
    Qi Wang
    Department of Respiratory Medicine, the Second Hospital affiliated to Dalian Medical University, Dalian 116023, China
    Anticancer Res 27:2359-64. 2007
    ..To investigate the relationship between the expression of glucose-regulated protein (GRP78) and resistance to VP-16 in the NCI-H460 cell line...
  52. ncbi Herbal extract "Songyou Yin" inhibits tumor growth and prolongs survival in nude mice bearing human hepatocellular carcinoma xenograft with high metastatic potential
    Xiu Yan Huang
    Department of General Surgery, The 6th People s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, China
    J Cancer Res Clin Oncol 135:1245-55. 2009
    ..This study evaluates the effect of the herbal compound extract "Songyou Yin" (containing Salvia miltiorrhiza Bge.-danshen and other four herbs) on hepatocellular carcinoma (HCC)...
  53. ncbi Study of the anticancer potential of Yemeni plants used in folk medicine
    R A A Mothana
    Department of Pharmacognosy, Faculty of Pharmacy, Sana a University, Yemen
    Pharmazie 62:305-7. 2007
    ..29 and 5.54 microg/ml. The extracts of Jatropha unicostata and Punica protopunica showed a moderate potency on the most tumor cell lines...
  54. ncbi The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel
    Ahmed Ashour Ahmed
    Functional Genomics of Drug Resistance Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Cancer Cell 12:514-27. 2007
    ..These data show that ECM can mediate taxane sensitivity by modulating microtubule stability...
  55. ncbi Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein
    F A De Jong
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 81:42-9. 2007
    ..As the association was seen in patients not genetically predisposed at risk for diarrhea due to UGT1A1*28, confirmatory studies of the relationships of ABCC2 genotypes and irinotecan disposition and toxicity are warranted...
  56. ncbi Cancer--an ayurvedic perspective
    Premalatha Balachandran
    National Center for Natural Products Research, Department of Pharmacognosy, University of Mississippi, MS 38677, USA
    Pharmacol Res 51:19-30. 2005
    ....
  57. ncbi Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations
    Giovanni Chillemi
    CASPUR Inter University Consortium for the Application of Super Computing for Universities and Research, Via dei Tizii 6, Rome 00185, Italy
    Nucleic Acids Res 36:5645-51. 2008
    ....
  58. ncbi Luteolin, a flavonoid with potential for cancer prevention and therapy
    Yong Lin
    Molecular Biology and Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr, SE, Albuquerque, NM 87108, USA
    Curr Cancer Drug Targets 8:634-46. 2008
    ..In this review, we summarize the progress of recent research on luteolin, with a particular focus on its anticancer role and molecular mechanisms underlying this property of luteolin...
  59. ncbi Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells
    Esha Madan
    Proteomics Laboratory, Indian Institute of Toxicology Research, Mahatma Gandhi Marg, P O Box 80, Lucknow, UP 226001, India
    Biochem Biophys Res Commun 377:1232-7. 2008
    ..These observations indicate that resveratrol treatment inhibits JAK/STAT-mediated gene transcription and induce the mitochondrial cell death pathway...
  60. ncbi Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma
    Ila Das
    Departments of Cancer Chemoprevention and Cancer Detection and Screening, Chittaranjan National Cancer Institute, Kolkata, India
    Nutrition 25:459-71. 2009
    ..In this report, we pursue the chemopreventive effect of aqueous garlic on skin carcinogenesis...
  61. ncbi Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
    Mary E R O'Brien
    Royal Marsden Hospital, London, United Kingdom
    J Thorac Oncol 3:728-34. 2008
    ..Paclitaxel poliglumex (PPX), a macromolecular polymer-drug conjugate of paclitaxel and poly-l-glutamic acid, may enhance the therapeutic index of paclitaxel...
  62. ncbi Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study
    Fung Ming Siu
    Department of Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, China
    J Am Chem Soc 130:17928-37. 2008
    ....
  63. ncbi Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells
    Ho Keun Kwon
    Department of Life Sciences, Gwangju Institute of Science and Technology, 1 Oryong dong, Puk ku, Gwangju, Republic of Korea
    Cancer Lett 278:174-82. 2009
    ..In conclusion, cinnamon extract has the potential to be an alternative medicine for tumor treatment...
  64. ncbi Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Naples, Italy
    J Clin Oncol 25:1377-82. 2007
    ....
  65. ncbi Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice
    Surajit Karmakar
    Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 325E, P O Box 250606, Charleston, SC 29425, USA
    Apoptosis 12:2077-87. 2007
    ..Our investigation revealed that treatment of glioblastoma T98G xenografts with the combination of ATRA and TXL induced differentiation and multiple molecular mechanisms for apoptosis...
  66. ncbi The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
    G J Weiss
    Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Ann Oncol 18:453-60. 2007
    ....
  67. ncbi [Progress in therapy for testicular tumors]
    Yoichi Mizutani
    Dept. of Urology, Kyoto Prefectural University of Medicine
    Gan To Kagaku Ryoho 33:183-7. 2006
    ..Some of the new modalities are very attractive. In this article, we reviewed mainly these new forms of chemotherapy for testicular tumors...
  68. ncbi Bcl-2 gene silencing in pediatric epithelial liver tumors
    Steven W Warmann
    Department of Pediatric Surgery, University Children s Hospital Tubingen, Tubingen, Germany
    J Surg Res 144:43-8. 2008
    ..The role of Bcl-2 proteins in these tumors is yet unclear. The purpose of this study was to analyze the influence of Bcl-2 on the chemotherapy resistance of hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC)...
  69. ncbi [Antitumor effect of docetaxel against human endometrial tumor cell lines]
    Shuji Shakuto
    Drug Safety Evaluation, Preclinical Development, Scientific Affairs, Aventis Pharma Ltd, Sanofi-Aventis Group
    Gan To Kagaku Ryoho 32:1437-42. 2005
    ..These results demonstrated that docetaxel shows potent antitumor efficacy against human endometrial tumor cell lines, leading to the expectation that it will be useful as a therapeutic agent for endometrial cancer...
  70. ncbi Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling
    Ami Albihn
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 121:1821-9. 2007
    ..In summary, our findings revealed that activation of PKCdelta in response to CPT treatment requires Myc and is important in CPT-mediated apoptosis signaling...
  71. ncbi Promising new agents in the treatment of non-small cell lung cancer
    M J Edelman
    Division of Hematology and Oncology, University of California, Davis, USA
    Cancer Chemother Pharmacol 37:385-93. 1996
    ..The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed...
  72. ncbi Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment
    Michael S Gee
    Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Int J Cancer 121:2492-500. 2007
    ..This multiparametric imaging approach has great potential in the clinical setting for determining patient eligibility, adequate drug dosing and early biological response of molecularly-targeted cancer therapies...
  73. ncbi In vitro cell cultures obtained from different explants of Corylus avellana produce Taxol and taxanes
    Federica Bestoso
    Laboratory of Plant and Pharmaceutical Biotechnology, Advanced Biotechnology Center ABC, Largo R Benzi, 10, 16132 Genova, Italy
    BMC Biotechnol 6:45. 2006
    ..For this purpose different explants of hazel (Corylus avellana species) were used to optimize the protocol for inducing in vitro callus, an undifferentiated tissue from which suspension cell cultures were established...
  74. ncbi Cytotoxic calanquinone A from Calanthe arisanensis and its first total synthesis
    Chia Lin Lee
    Natural Products Research Laboratories, School of Pharmacy, University of North Carolina at Chapel Hill, 315 Beard Hall, CB 7360, NC 27599 7360, USA
    Bioorg Med Chem Lett 18:4275-7. 2008
    ..The total synthesis of 1 was also achieved and is reported herein...
  75. ncbi Luteolin induces apoptosis in oral squamous cancer cells
    S F Yang
    Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    J Dent Res 87:401-6. 2008
    ..These results suggest that luteolin could be an effective chemotherapeutic agent for the treatment of oral squamous cell carcinoma...
  76. ncbi Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells
    Sharon J Olijslagers
    Biological Chemistry, Leiden University, Leiden, The Netherlands
    Basic Clin Pharmacol Toxicol 100:127-31. 2007
    ..Our results indicate that the cytotoxicity-enhancing action by the tumour-specific apoptin in combination with chemotherapeutic agents might offer an effective and safe antitumour therapeutics...
  77. ncbi Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung
    Yutaka Fujiwara
    Divisions of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 37:482-6. 2007
    ..The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear...
  78. ncbi Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
    Limin Hu
    Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143-0556, USA
    Clin Cancer Res 11:6966-71. 2005
    ..9 +/- 38.88 days with no further treatment. We conclude that combination therapy with VEGF Trap plus paclitaxel may provide a novel, long-lasting therapeutic strategy for treatment of patients with ovarian cancer associated with ascites...
  79. ncbi Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3
    H J Muenchen
    Department of Internal Medicine (Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Urology 57:366-70. 2001
    ..CONCLUSIONS: In this study, we demonstrated two distinctly different Taxotere-induced apoptotic pathways in LNCaP and PC-3 cells that may be of clinical importance when treating prostate cancer...
  80. ncbi Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel
    Geertruida M Kolfschoten
    Department of Medical Oncology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Biochem Pharmacol 63:733-43. 2002
    ..We conclude that docetaxel is able to activate caspase-3, induce Bcl-2 phosphorylation and apoptosis in cells that show a prolonged G2/M arrest, but cells may also die by a caspase-3-independent cell death mechanism...
  81. ncbi Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary
    Hiroaki Itamochi
    Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago 683 8504
    Jpn J Cancer Res 93:723-8. 2002
    ..The present study revealed several resistance mechanisms in CCC and the results suggested that PTX and CPT-11 might be effective agents to treat CCC...
  82. ncbi In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Breast Cancer Res Treat 74:41-6. 2002
    ....
  83. ncbi Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer
    Mark R Green
    Department of Medicine, Medical University of South Carolina, Charleston 29425, USA
    Semin Oncol 29:17-21. 2002
    ..There is also considerable promise in combining docetaxel with any of the large number of molecularly targeted therapies now becoming available...
  84. ncbi New highly active taxoids from 9beta-dihydrobaccatin-9,10-acetals. Part 2
    Takashi Ishiyama
    Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co, Ltd, Tokyo R and D Center, 16-13 Kita-kasai 1-Chome Edogawa-ku, Tokyo, Japan
    Bioorg Med Chem Lett 12:2815-9. 2002
    ..In addition, we found that the 7-deoxy-3'-(4-pyridyl) and 7-deoxy-3'-(2-pyridyl) analogues showed stronger activity against cell lines expressing P-glycoprotein than the corresponding 3'-phenyl analogue...
  85. ncbi Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer
    N Zaffaroni
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    Cell Mol Life Sci 59:1406-12. 2002
    ..Cellular studies and clinical data suggest a direct link between survivin expression and tumour cell susceptibility to taxol...
  86. ncbi Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms
    Hui Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA
    Prostate 54:194-205. 2003
    ....
  87. ncbi In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines
    Luca Ricotti
    Istituto Oncologico Romagnolo, , Italy
    Clin Cancer Res 9:900-5. 2003
    ..CONCLUSIONS: Our findings suggest that the interaction of DOC and GEM is highly schedule dependent and has been used recently to plan a Phase I-II clinical protocol...
  88. ncbi Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells
    Lois M Witters
    Departments of Medicine, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
    Am J Clin Oncol 26:50-4. 2003
    ..In contrast, the cytotoxic effects of docetaxel in these breast carcinoma cells are not affected by HER-2/neu expression. Therefore, docetaxel may be the preferred taxane therapy in HER-2/neu overexpressing breast tumors...
  89. ncbi Anticancer activity of docetaxel in murine salivary gland carcinoma
    Marie P Piechocki
    Department of Otolaryngology Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Clin Cancer Res 8:870-7. 2002
    ..The purpose of this study was to evaluate the biological mechanisms of docetaxel (TXT) on salivary gland carcinoma...
  90. ncbi Gemcitabine-based combination treatment of pancreatic cancer
    Volker Heinemann
    Klinikum Grosshadern, III Medical Clinic, Munich, Germany
    Semin Oncol 29:25-35. 2002
    ..Four-drug regimens indicate a possible improvement in treatment outcome. However, their application may be limited to selected patients with good performance status...
  91. ncbi Orally active docetaxel analogue: synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues
    S Iimura
    New Product Research Laboratories IV, Daiichi Pharmaceutical Co, Ltd, Tokyo, Japan
    Bioorg Med Chem Lett 11:407-10. 2001
    ..Among these analogues, the 7-methoxy analogue showed the strongest cytotoxicity. This analogue showed potent activity against B16 melanoma BL6 in vivo by oral administration...
  92. ncbi A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes
    G Cassinelli
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Int J Cancer 92:738-47. 2001
    ..These events, more evident after exposure to the potent analog IDN 5109, support the notion that the enhanced sensitivity of p53 mutant cells is closely related to the different mode of cell death...
  93. ncbi Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells
    A Nehme
    Department of Medicine and the Cancer Center, University of California, 9500 Gilman Drive, San Diego, La Jolla, CA 92093 0058, USA
    Br J Cancer 84:1571-6. 2001
    ....
  94. ncbi Rationale for non-platinum chemotherapy in advanced NSCLC
    J R Murren
    Department of Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Oncology (Williston Park) 15:29-34. 2001
    ....
  95. ncbi Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance
    M R Vredenburg
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Natl Cancer Inst 93:1234-45. 2001
    ..003). CONCLUSIONS: IDN-5109 modulates Pgp activity, resulting in superior tumor growth inhibition against Pgp-expressing tumors as compared with paclitaxel. IDN-5109 may broaden the spectrum of taxane use to include colon tumors...
  96. ncbi The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells
    J S Kim
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5671, USA
    Int J Radiat Oncol Biol Phys 51:525-34. 2001
    ..These data also support the hypothesis that a G2/M block is involved in the radiosensitization caused by the taxanes...
  97. ncbi Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens
    Y Shigeoka
    Division of Oncology/Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 31:370-4. 2001
    ..We will evaluate irinotecan for advanced and metastatic breast cancer patients as first- or second-line chemotherapy combined with anthracycline or taxane...
  98. ncbi [Docitaxol-induction apoptosis of osteosarcoma]
    L Peng
    Institute of Orthopaedics of PLA, Xijing Hospital, Xi'an 710032, China
    Zhonghua Zhong Liu Za Zhi 23:190-2. 2001
    ..CONCLUSION: The growth inhibiting effect of docitaxol is due to its ability to induce apoptosis. It shows great potential in the treatment of osteosarcoma...
  99. ncbi Semi-synthesis of an O-glycosylated docetaxel analogue
    Anastasia Nikolakakis
    Human Health Research Center, INRS-Institut Armand-Frappier, , 531 Boulevard des Prairies, Laval, , Canada H7V 1B7
    Bioorg Med Chem 11:1551-6. 2003
    ..In addition, the presence of one sugar moiety on C-7 doubled the water solubility versus that of paclitaxel...
  100. ncbi Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs
    Kazuaki Tanabe
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734 8553, Japan
    Int J Oncol 22:875-81. 2003
    ....
  101. ncbi Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer
    Hiromitsu Yabushita
    Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute cho, Aichi Gun, Aichi 480 1195, Japan
    Oncol Rep 12:307-11. 2004
    ..In conclusion, CD-DST results reflect clinical outcomes and may be a useful means by which to select drugs to which ovarian cancer cells are chemosensitive...

Research Grants123 found, 100 shown here

  1. Molecular Target Focused Discovery of Anticancer Drugs
    George R Pettit; Fiscal Year: 2010
    ....
  2. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2007
    ..In summary, the proposed research will be sharply aimed at the discovery and very rapid development of new anticancer drugs for the NCI programs direct at improving human cancer treatments. ..
  3. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2005
    ..In summary, the proposed research will be sharply aimed at the discovery and very rapid development of new anticancer drugs for the NCI programs directed at improving human cancer treatments. ..
  4. Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
    Lars Wagner; Fiscal Year: 2007
    ..We hypothesize this strategy will be well tolerated and allow for meaningful dose escalation through chemoprotection afforded by gene transfer into hematopoietic stem cells. ..
  5. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  6. Design of Gene Delivery System to Target Hepatocytes
    Mark Davis; Fiscal Year: 2007
    ..The long-term objective of our proposal is to design and engineer a generalized, synthetic system for ultimately delivering nucleic acid-based therapeutics to hepatocytes in humans. ..
  7. NATIONAL WILMS TUMOR STUDY -5
    Daniel Green; Fiscal Year: 2003
    ..The survival of most children treated for WT allows the study of genetic and treatment factors associated with the etiology of the disease and/or the occurrence of complications of therapy. ..
  8. Phase I Clinical Trials of Anti-Cancer Agents
    Mark Ratain; Fiscal Year: 2007
    ..This application also includes a proposal for the creation of an Early Clinical Trials Network to facilitate inter-institutional collaborations involving NCI-sponsored early clinical trials. ..
  9. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2007
    ....
  10. Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal Carcinoma
    Bach Ardalan; Fiscal Year: 2007
    ..Aim 2: Determine if ATO administration down regulates the expression of thymidylate synthase in tumor and in PBMC in patients receiving ATO + 5-FU. ..
  11. Neural Progenitor Cells as Cancer Therapy Vectors
    MARY DANKS; Fiscal Year: 2007
    ..The described approach might then be adapted to the treatment of other solid tumors by careful choice of appropriate therapeutic transgenes. ..
  12. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2007
    ....
  13. MECHANISM OF ACTION OF THE ANTITUMOR DRUG TAXOL
    Mary Jordan; Fiscal Year: 2002
    ..Understanding the linkage between microtubule dynamics, mitotic block, and resistance to taxol promises to lead to new drug targets that will improve the efficacy of chemotherapy. ..
  14. TNF Blockade in Pancreatic Cancer Patients
    MIGUEL VILLALONA; Fiscal Year: 2004
    ..The observation of benefits in either quality of life or progression-free survival in patients undergoing TNF blockade would encourage evaluation of this novel strategy in properly powered randomized clinical trials. ..
  15. Biomodulation of capecitabine by docetaxel in non-small*
    MIGUEL VILLALONA; Fiscal Year: 2005
    ..Confirmation of our working hypothesis may lead to a new treatment paradigm suitable for evaluation in the adjuvant setting. ..
  16. LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORS
    Francisco Esteva; Fiscal Year: 2003
    ..Gabriel Lopez-Berestein (Department of Bioimmunotherapy). M. D. Anderson Cancer Center has the patients and resources necessary for Dr. Esteva to successfully complete this research project. ..
  17. Pharmacogenetic Determinants of Vinca Alkaloid Response
    Jamie Renbarger; Fiscal Year: 2005
    ....
  18. SYNTHESIS AND BIOSYNTHESIS IN THE SHIKIMATE PATHWAY
    Bruce Ganem; Fiscal Year: 1999
    ..The corresponding syn-stereoisomer will be synthesized and evaluated, since SN2' displacements are known to occur with either syn or antistereochemistry in nonenzymatic systems. ..
  19. CLINICAL THERAPEUTICS
    Mark Ratain; Fiscal Year: 2007
    ..abstract_text> ..
  20. Mitochondrial Oxidative Stress In Angiotensis II Induced Endothelial Dysfunction
    Sergey Dikalov; Fiscal Year: 2010
    ..This work will study the role of mitochondrial oxidative stress in endothelial dysfunction and provide a novel therapeutic target to treat and prevent hypertension. ..
  21. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
  22. Targeting Somatic Homologous Recombination in Solid Tumors
    MIGUEL ANGEL VILLALONA; Fiscal Year: 2010
    ..We hypothesize that these patients will derive substantial clinical benefit from such treatment. ..
  23. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2007
    ..These studies are critical for establishing which biomarkers are useful in predicting patient response and monitoring treatment progress, as well as forming a baseline for biomarker studies for future trials with anti-VEGF therapies. ..
  24. MENTORING & ADVANCED RESEARCH TRAINING FOR WRHR SCHOLARS
    Jonathan Berek; Fiscal Year: 2007
    ..This cadre of Scholars will be among future leaders in women's reproductive health research in the United States. ..
  25. Resveratrol-induced apoptotic cell death in glioma
    Hao Jiang; Fiscal Year: 2007
    ..By elucidating the molecular mechanisms underlying the therapeutic effects of resveratrol, this study would facilitate the development of therapeutic agents using natural products and greatly improve the treatment of brain tumors. ..
  26. PHARMACOGENETICS OF ANTICANCER AGENTS RESEARCH GROUP
    Mark Ratain; Fiscal Year: 2007
    ....
  27. A Novel Method of Nanoparticle Delivery to Brain by Targeting Ec-gp96
    Mark E Davis; Fiscal Year: 2010
    ....
  28. Non-Viral Vectors for Liver Gene Transfer
    Feng Liu; Fiscal Year: 2006
    ..The therapeutic effects on the metabolic disease on phenylketonuria (PKU) mice, will be examined after the PAH gene transfer using the approach in this proposal. ..
  29. Identification of Anti-Viral Compounds from Plants
    Shiyou Li; Fiscal Year: 2005
    ..abstract_text> ..
  30. MOLECULAR DETERMINANTS OF MULTICELLULAR ORGANIZATION
    Douglas Hixson; Fiscal Year: 1992
    ..These studies will provide new insight into molecular events involved in the formation of histotypic interactions and changes in these events that lead to the aberrant interactions characteristic of malignant cells...
  31. CELLULAR ORIGINS OF LIVER CANCER
    Douglas Hixson; Fiscal Year: 1993
    ..Identification of unique integration sites held in common between oval cells and hepatocytes, focal lesions, nodules or primary tumors will provide unequivocal evidence for precursor-product relationships...
  32. Genesis of Liver Carcinomas with Oval Cell Traits
    Douglas Hixson; Fiscal Year: 2007
    ..We will test the hypothesis that loss of BD.1 alters microtubule/kinetochore dynamics in a manner that promotes aneuploidy. The proposed studies will provide new insights into the role of bipotent progenitors in liver cancer. ..
  33. CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Mark Ratain; Fiscal Year: 2002
    ..Since many of the studies include analysis of pharmacological specimens, the Committee utilizes three core laboratories--at the University of Chicago, the University of Maryland and the University of Tennessee. ..
  34. MOLECULAR DETERMINANTS OF MULTICELLULAR ORGANIZATION
    Douglas Hixson; Fiscal Year: 2003
    ..The proposed studies will provide new insights into the role of C-CAM in the interactions of normal hepatocytes and the consequences of the loss of C-CAM during liver carcinogenesis. ..